Impact of rituximab on treatment outcomes of patients with diffuse large b-cell lymphoma: A population-based analysis

British Journal of Haematology

Volumn 158, Issue 4, 2012, Pages 481-488

  Lee, Linda ^a   Crump, Michael ^b   Khor, Sara ^c,d   Hoch, Jeffrey S ^c,d   Luo, Jin ^e   Bremner, Karen ^f   Krahn, Murray ^f,g   Hodgson, David C ^b,g  

^a Systeme de sante de Niagara   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c CANCER CARE ONTARIO   (Canada)

^d ST MICHAEL'S HOSPITAL   (Canada)

^e INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^f TORONTO GENERAL HOSPITAL   (Canada)

^g UNIVERSITY OF TORONTO   (Canada)

Author keywords

Diffuse large B cell lymphoma; Elderly; Outcomes; Rituximab; Toxicity

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGE DISTRIBUTION; AGED; ANGINA PECTORIS; ARTICLE; CANADA; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; COGNITIVE DEFECT; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ENTEROPATHY; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL DISEASE; HEART ARRHYTHMIA; HEART DISEASE; HEPATITIS; HISTOPATHOLOGY; HOSPITALIZATION; HUMAN; HUMAN TISSUE; INFECTION; INTERSTITIAL LUNG DISEASE; LARGE CELL LYMPHOMA; LEUKOENCEPHALOPATHY; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MUCOCUTANEOUS LYMPH NODE SYNDROME; MULTIPLE CYCLE TREATMENT; NEUROLOGIC DISEASE; OVERALL SURVIVAL; PNEUMONIA; POPULATION RESEARCH; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK REDUCTION; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HOSPITALIZATION; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PREDNISONE; REGISTRIES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VINCRISTINE; YOUNG ADULT;

EID: 84864297051     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2012.09177.x     Document Type: Article

References (21)

1. Austin, P.C. (2009) Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Statistics in Medicine, 28, 3083-3107.
2. Carson, K.R., Evens, A.M., Richey, E.A., Habermann, T.M., Focosi, D., Seymour, J.F., Laubach, J., Bawn, S.D., Gordon, L.I., Winter, J.N., Furman, R.R., Vose, J.M., Zelenetz, A.D., Mamtani, R., Raisch, D.W., Dorshimer, G.W., Rosen, S.T., Muro, K., Gottardi-Littell, N.R., Talley, R.L., Sartor, O., Green, D., Major, E.O. & Bennett, C.L. (2009) Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood, 113, 4834-4840.
3. Clarke, C.A., Undurraga, D.M., Harasty, P.J., Glaser, S.L., Morton, L.M. & Holly, E.A. (2006) Changes in cancer registry coding for lymphoma subtypes: reliability over time and relevance for surveillance and study. Cancer Epidemiology, Biomarkers & Prevention, 15, 630-638.
4. Coebergh, J.W., Janssen-Heijnen, M.L., Post, P.N. & Razenberg, P.P. (1999) Serious co-morbidity among unselected cancer patients newly diagnosed in the southeastern part of The Netherlands in 1993-1996. Journal Clinical Epidemiology, 52, 1131-1136.
5. Coiffier, B., Lepage, E., Briere, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., Reyes, F., Lederlin, P. & Gisselbrecht, C. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. New England Journal of Medicine, 346, 235-242
6. Coiffier, B., Thieblemont, C., Van Den Neste, E., Lepeu, G., Plantier, I., Castaigne, S., Lefort, S., Marit, G., Macro, M., Sebban, C., Belhadj, K., Bordessoule, D., Ferme, C. & Tilly, H. (2010) Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood, 116, 2040-2045.
7. Committee on the Assessment of the US Drug Safety System (2006) The future of drug safety: Promoting and proctecting the health of the public. (ed. by A. Baciu, K. Stratton & S.P. Burke ), pp. 2. The National Academies Press, Washington, D.C.
8. Ennishi, D., Maeda, Y., Niitsu, N., Kojima, M., Izutsu, K., Takizawa, J., Kusumoto, S., Okamoto, M., Yokoyama, M., Takamatsu, Y., Sunami, K., Miyata, A., Murayama, K., Sakai, A., Matsumoto, M., Shinagawa, K., Takaki, A., Matsuo, K., Kinoshita, T. & Tanimoto, M. (2010) Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis. Blood, 116, 5119-5125.
9. Feugier, P., Van Hoof, A., Sebban, C., Solal-Celigny, P., Bouabdallah, R., Ferme, C., Christian, B., Lepage, E., Tilly, H., Morschhauser, F., Gaulard, P., Salles, G., Bosly, A., Gisselbrecht, C., Reyes, F. & Coiffier, B. (2005) Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. Journal of Clinical Oncology, 23, 4117-4126.
10. Habermann, T.M., Weller, E.A., Morrison, V.A., Gascoyne, R.D., Cassileth, P.A., Cohn, J.B., Dakhil, S.R., Woda, B., Fisher, R.I., Peterson, B.A. & Horning, S.J. (2006) Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. Journal of Clinical Oncology, 24, 3121-3127.
11. Katsuya, H., Suzumiya, J., Sasaki, H., Ishitsuka, K., Shibata, T., Takamatsu, Y. & Tamura, K. (2009) Addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy has a high risk of developing interstitial pneumonia in patients with non-Hodgkin lymphoma. Leukemia & Lymphoma, 50, 1818-1823.
12. Klein, J.P. & Moeschberger, M.L. (1997) Survival analysis: techniques for censored and truncated data. Springer-Verlag, New York.
13. Liu, X., Hong, X.N., Gu, Y.J., Wang, B.Y., Luo, Z.G. & Cao, J. (2008) Interstitial pneumonitis during rituximab-containing chemotherapy for non-Hodgkin lymphoma. Leukemia & Lymphoma, 49, 1778-1783.
14. Niitsu, N., Hagiwara, Y., Tanae, K., Kohri, M. & Takahashi, N. (2010) Prospective analysis of hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma after rituximab combination chemotherapy. Journal of Clinical Oncology, 28, 5097-5100.
15. Pfreundschuh, M., Trumper, L., Osterborg, A., Pettengell, R., Trneny, M., Imrie, K., Ma, D., Gill, D., Walewski, J., Zinzani, P.L., Stahel, R., Kvaloy, S., Shpilberg, O., Jaeger, U., Hansen, M., Lehtinen, T., Lopez-Guillermo, A., Corrado, C., Scheliga, A., Milpied, N., Mendila, M., Rashford, M., Kuhnt, E. & Loeffler, M. (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. The Lancet Oncology, 7, 379-391.
16. Pfreundschuh, M., Schubert, J., Ziepert, M., Schmits, R., Mohren, M., Lengfelder, E., Reiser, M., Nickenig, C., Clemens, M., Peter, N., Bokemeyer, C., Eimermacher, H., Ho, A., Hoffmann, M., Mertelsmann, R., Trumper, L., Balleisen, L., Liersch, R., Metzner, B., Hartmann, F., Glass, B., Poeschel, V., Schmitz, N., Ruebe, C., Feller, A.C. & Loeffler, M. (2008) Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). The Lancet Oncology, 9, 105-116.
17. Ram, R., Ben-Bassat, I., Shpilberg, O., Polliack, A. & Raanani, P. (2009) The late adverse events of rituximab therapy-rare but there!. Leukemia & Lymphoma, 50, 1083-1095.
18. Sehn, L.H., Donaldson, J., Chhanabhai, M., Fitzgerald, C., Gill, K., Klasa, R., MacPherson, N., O'Reilly, S., Spinelli, J.J., Sutherland, J., Wilson, K.S., Gascoyne, R.D. & Connors, J.M. (2005) Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. Journal of Clinical Oncology, 23, 5027-5033.
19. Seruga, B., Sterling, L., Wang, L. & Tannock, I.F. (2011) Reporting of serious adverse drug reactions of targeted anticancer agents in pivotal phase III clinical trials. Journal of Clinical Oncology, 29, 174-185.
20. Starfield, B., Weiner, J., Mumford, L. & Steinwachs, D. (1991) Ambulatory care groups: a categorization of diagnoses for research and management. Health Services Research, 26, 53-74.
21. Townsley, C.A., Selby, R. & Siu, L.L. (2005) Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials. Journal of Clinical Oncology, 23, 3112-3124.